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Although organic nitrates continue to be widely used in
the therapy of cardiovascular disease there is increasing
evidence that their long-term use is associated with
adverse vascular effects. The phenomenon of tolerance,
whereby the vascular, hemodynamic and clinical effec-
tiveness of the nitrates is lost during sustained therapy,
has been recognized for almost 30 years. Recent studies
have documented that sustained therapy with glyceryl
trinitrate (GTN) is associated with increased vascular free
radical formation and the development of endothelial
dysfunction. These findings have been documented in
animal models as well as in the human coronary and fore-
arm circulation. Paradoxically the acute and short-term
administration of organic nitrates appears to have benefi-
cial effects on vascular function. When given in very low
doses GTN augments the effects of endothelium-depend-
ent vasodilators. Furthermore, there is now clear evidence
that short-term (1–2 hours) exposure to GTN provides
protection from ischemic injury at time points 24 to 48
hours later. This pharmacologic preconditioning effect
appears to be mediated by the production of reactive oxy-
gen species as it can be blocked by the co-administration
of vitamin C. The finding that administration of sildenafil
affords protection from the impact of ischemic insults
emphasizes the importance of cyclic GMP in the media-
tion of pharmacologic preconditioning. In order to
address this question we used a human forearm model of
ischemic vascular injury where the impact of 15 minutes
of forearm ischemia followed by reperfusion on flow-
mediated radial artery dilation is used as the marker of
ischemic injury. This ischemia reperfusion insult causes
almost complete loss of flow mediated brachial artery dil-
atation. In a double blind, placebo controlled trial we
have documented that the administration of sildenafil
just prior to ischemia reperfusion provides complete pro-
tection from the impact of ischemia on flow-mediated dil-
atation (figure 1). This effect appears to be dependent on
mitochondrial potassium ATP channels as the protective
effect of sildenafil could be completed inhibited by the co-
administration of the sulfonylurea glibenclamide.
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Flow-mediated dilatation of the radial artery (FMD %) before 
and after 15 min. of forearm ischemia and reperfusion (IR) in 
the presence and absence of sildenafil.
